[EN] COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS<br/>[FR] COMPOSÉS ET COMPOSITIONS UTILES EN TANT QU'AGONISTES DU RÉCEPTEUR 7 DE TYPE TOLL
申请人:NOVARTIS AG
公开号:WO2015168279A1
公开(公告)日:2015-11-05
The invention provides compounds of formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.
Beta-alanine derivatives and their use as receptor anatgonists
申请人:——
公开号:US20030018193A1
公开(公告)日:2003-01-23
A beta-alanine derivative of the formula (I) wherein R
1
is hydrogen atom or an amino protective group; A is a lower alkylene group or a lower alkenylene group; R
2
is hydrogen atom or an amino group which may be substituted with an acyl group; R
3
is hydrogen atom or an aryl or aralkyl group which may be substituted with one or more of hydroxy and/or lower alkoxy, a moiety represented by the formula (II), which is a bivalent N-containing 6- to 8-membered heterocyclic group, or a pharmaceutically acceptable salt thereof.
A novel method for the synthesis of 2,2-dimethyl-1,3-dioxolan-4-one, as well as the syntheses of amides of glycolic acid via its reaction with secondaryamines, is described.
Gamma radiolysis of hydrophilic diglycolamide ligands in concentrated aqueous nitrate solution
作者:Gregory P. Horne、Andreas Wilden、Stephen P. Mezyk、Liam Twight、Michelle Hupert、Andrea Stärk、Willem Verboom、Bruce J. Mincher、Giuseppe Modolo
DOI:10.1039/c9dt03918j
日期:——
and (iii) radiolysis is driven by hydroxyl and nitrate radical oxidation chemistry moderated by secondary degradation product scavenging reactions. Overall, the radiolysis of hydrophilic DGAs in concentrated, aqueous nitrate solutions is significantly slower and less structurally sensitive than under pure water conditions, similar to their lipophilic analogs. Acid hydrolysis, not radiolysis, is expected
There is provided compounds of formula I,
R
1
O(O)C—CH
2
—(R)Cgl-Aze-Pab-R
2
I
wherein R
1
and R
2
have meanings given in the description, which are useful as prodrugs of inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (eg thrombosis) or as anticoagulants.